Tags

Type your tag names separated by a space and hit enter

In Vitro Activity of Ceftazidime-Avibactam against Carbapenem-Resistant and Hypervirulent Klebsiella pneumoniae Isolates.
Antimicrob Agents Chemother. 2018 08; 62(8)AA

Abstract

Carbapenem-resistant and hypervirulent Klebsiella pneumoniae (CR-hvKp) strains have emerged while antimicrobial treatment options remain limited. Herein, we tested the in vitro activity of ceftazidime-avibactam and other comparator antibiotics against 65 CR-hvKp isolates. Ceftazidime-avibactam, colistin, and tigecycline are highly active in vitro against CR-hvKp isolates (MIC90, ≤1 μg/ml), including K. pneumoniae carbapenemase 2 (KPC-2)-producing ST11 CR-hvKp. On the basis of previous clinical experience and the in vitro data presented herein, we posit that ceftazidime-avibactam is a therapeutic option against CR-hvKp infections.

Authors+Show Affiliations

Department of Clinical Laboratory, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China. Department of Laboratory Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.Department of Laboratory Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.Department of Laboratory Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.Department of Clinical Laboratory, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.Department of Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA. Department of Pathology and Laboratory Medicine, Weill Medical College of Cornell University, New York, New York, USA.Case VA Center for Antimicrobial Resistance and Epidemiology (CARES), Case Western Reserve University, Cleveland, Ohio, USA. Research Service, Louis Stokes Cleveland VA Medical Center, Cleveland, Ohio, USA. Department of Medicine, Case Western Reserve University, Cleveland, Ohio, USA. Department of Pharmacology, Case Western Reserve University, Cleveland, Ohio, USA. Department of Molecular Biology and Microbiology, Case Western Reserve University, Cleveland, Ohio, USA.Public Health Research Institute Tuberculosis Center, New Jersey Medical School, Rutgers University, Newark, New Jersey, USA.Public Health Research Institute Tuberculosis Center, New Jersey Medical School, Rutgers University, Newark, New Jersey, USA Chen11@njms.rutgers.edu.

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.

Language

eng

PubMed ID

29891605

Citation

Yu, Fangyou, et al. "In Vitro Activity of Ceftazidime-Avibactam Against Carbapenem-Resistant and Hypervirulent Klebsiella Pneumoniae Isolates." Antimicrobial Agents and Chemotherapy, vol. 62, no. 8, 2018.
Yu F, Lv J, Niu S, et al. In Vitro Activity of Ceftazidime-Avibactam against Carbapenem-Resistant and Hypervirulent Klebsiella pneumoniae Isolates. Antimicrob Agents Chemother. 2018;62(8).
Yu, F., Lv, J., Niu, S., Du, H., Tang, Y. W., Bonomo, R. A., Kreiswirth, B. N., & Chen, L. (2018). In Vitro Activity of Ceftazidime-Avibactam against Carbapenem-Resistant and Hypervirulent Klebsiella pneumoniae Isolates. Antimicrobial Agents and Chemotherapy, 62(8). https://doi.org/10.1128/AAC.01031-18
Yu F, et al. In Vitro Activity of Ceftazidime-Avibactam Against Carbapenem-Resistant and Hypervirulent Klebsiella Pneumoniae Isolates. Antimicrob Agents Chemother. 2018;62(8) PubMed PMID: 29891605.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - In Vitro Activity of Ceftazidime-Avibactam against Carbapenem-Resistant and Hypervirulent Klebsiella pneumoniae Isolates. AU - Yu,Fangyou, AU - Lv,Jingnan, AU - Niu,Siqiang, AU - Du,Hong, AU - Tang,Yi-Wei, AU - Bonomo,Robert A, AU - Kreiswirth,Barry N, AU - Chen,Liang, Y1 - 2018/07/27/ PY - 2018/05/17/received PY - 2018/06/05/accepted PY - 2018/6/13/pubmed PY - 2019/9/24/medline PY - 2018/6/13/entrez KW - carbapenem resistance KW - ceftazidime-avibactam KW - hypervirulent Klebsiella pneumoniae KW - susceptibility JF - Antimicrobial agents and chemotherapy JO - Antimicrob Agents Chemother VL - 62 IS - 8 N2 - Carbapenem-resistant and hypervirulent Klebsiella pneumoniae (CR-hvKp) strains have emerged while antimicrobial treatment options remain limited. Herein, we tested the in vitro activity of ceftazidime-avibactam and other comparator antibiotics against 65 CR-hvKp isolates. Ceftazidime-avibactam, colistin, and tigecycline are highly active in vitro against CR-hvKp isolates (MIC90, ≤1 μg/ml), including K. pneumoniae carbapenemase 2 (KPC-2)-producing ST11 CR-hvKp. On the basis of previous clinical experience and the in vitro data presented herein, we posit that ceftazidime-avibactam is a therapeutic option against CR-hvKp infections. SN - 1098-6596 UR - https://www.unboundmedicine.com/medline/citation/29891605/In_Vitro_Activity_of_Ceftazidime_Avibactam_against_Carbapenem_Resistant_and_Hypervirulent_Klebsiella_pneumoniae_Isolates_ L2 - http://aac.asm.org/cgi/pmidlookup?view=long&pmid=29891605 DB - PRIME DP - Unbound Medicine ER -